Cognitive Assessment: Delirium, Dementia & Mild Cognitive Impairment
Key Takeaways
- Delirium is an acute, fluctuating cognitive disturbance with inattention requiring CAM criteria (acute onset, fluctuating course, inattention, plus disorganized thinking or altered consciousness).
- Alzheimer's disease treatment involves cholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine) for mild-to-moderate stages and Memantine (NMDA antagonist) for moderate-to-severe disease.
- Lewy Body Dementia features visual hallucinations, parkinsonism, REM sleep behavior disorder, and life-threatening neuroleptic sensitivity to typical antipsychotics.
- Vascular dementia is characterized by a stepwise cognitive decline tied to cerebrovascular events and cardiovascular risk factors.
- The MoCA is the most sensitive screening tool for Mild Cognitive Impairment (MCI) and executive dysfunction, whereas the Mini-Cog provides rapid clinic screening.
Cognitive Assessment and Neurocognitive Disorders
Evaluating cognitive complaints in adult and older adult populations is a cornerstone of primary care and gerontological nursing practice. Patients frequently present with memory loss, word-finding difficulty, spatial disorientation, or behavioral changes. The primary care nurse practitioner (NP) must systematically differentiate between benign age-associated memory impairment, subjective cognitive decline (SCD), mild cognitive impairment (MCI), dementia (major neurocognitive disorder), and acute medical syndromes such as delirium and depression.
Mild Cognitive Impairment (MCI) and Reversible Causes
Mild Cognitive Impairment (MCI) represents an intermediate stage between normal cognitive aging and early dementia. Patients with MCI exhibit objectively measured cognitive decline in one or more cognitive domains (memory, executive function, attention, language, or visuospatial skills) greater than expected for age and education level. Crucially, individuals with MCI retain independence in basic and instrumental activities of daily living (ADLs and IADLs), though tasks may require compensatory strategies. MCI is subclassified into amnestic MCI (predominantly memory impairment, carrying a 10% to 15% annual conversion rate to Alzheimer's disease) and non-amnestic MCI (executive function or language deficits).
Prior to diagnosing irreversible neurocognitive decline, NPs must complete a comprehensive evaluation to rule out secondary, treatable causes of cognitive dysfunction:
- Metabolic and Endocrine: Hypothyroidism (evaluated with serum TSH) and hypercalcemia.
- Nutritional Deficiencies: Vitamin B12 deficiency (serum B12 < 200 pg/mL confirms deficiency; levels between 200–400 pg/mL require serum methylmalonic acid [MMA] testing).
- Infectious Disease: Neurosyphilis (rapid plasma reagin [RPR]) and HIV-associated neurocognitive disorder.
- Structural Lesions: Subdural hematoma, normal pressure hydrocephalus (NPH—classic triad of gait ataxia, urinary incontinence, and dementia: "wobbly, wet, and wacky"), or intracranial mass lesions, evaluated via non-contrast head CT or brain MRI.
- Medication Toxicity & Polypharmacy: Anticholinergic drugs, sedatives, central nervous system depressants, and polypharmacy.
Diagnostic Triad: Delirium, Dementia, and Depression
Differentiating among delirium, dementia, and depression (pseudodementia) is essential because management strategies and clinical urgencies differ drastically.
| Diagnostic Feature | Delirium | Dementia | Depression (Pseudodementia) |
|---|---|---|---|
| Onset | Acute (hours to days) | Insidious (months to years) | Subacute (weeks to months) |
| Course | Fluctuating; worse at night ("sundowning") | Chronically progressive; stable day-to-day | Diurnal variation; worse in the morning |
| Consciousness | Altered (hyperactive, hypoactive, or mixed) | Clear and alert until end-stage | Clear and alert |
| Attention | Markedly impaired; severe inattention | Intact until advanced disease stages | Intact, though patient may seem distracted |
| Reversibility | Potentially fully reversible | Generally irreversible and progressive | Fully reversible with psychiatric treatment |
| Testing Effort | Fluctuating, inconsistent responses | Tries hard to answer; may confabulate | Highlights deficits; frequent "I don't know" answers |
Delirium Assessment and Clinical Management
Delirium is a medical emergency representing acute, transient brain dysfunction triggered by underlying physiological stressors, acute illness, or drug toxicity.
The Confusion Assessment Method (CAM) is the gold-standard bedside diagnostic instrument. A positive CAM diagnosis requires:
- Feature 1: Acute Onset and Fluctuating Course (sudden change in mental status that fluctuates), AND
- Feature 2: Inattention (difficulty focusing or maintaining attention), PLUS either:
- Feature 3: Disorganized Thinking (incoherent speech), OR
- Feature 4: Altered Level of Consciousness (hyperalert, lethargic, or comatose).
Common precipitants of delirium are summarized by the mnemonic DELIRIUMS:
- Drugs (anticholinergics, benzodiazepines, opioids, sedative-hypnotics, diphenhydramine)
- Electrolyte imbalances (hyponatremia, hypercalcemia, dehydration)
- Lack of drugs/withdrawal (alcohol or benzodiazepine withdrawal)
- Infection (urinary tract infection [UTI], pneumonia, sepsis)
- Reduced sensory input (uncorrected vision or hearing loss)
- Intracranial pathology (stroke, TIA, subdural hematoma)
- Urinary retention or fecal impaction
- Myocardial or pulmonary events (MI, heart failure, hypoxia, hypercapnia)
- Surgery or severe unmanaged pain
Management: Non-pharmacological interventions are first-line, including reorientation, early mobilization, sleep hygiene, and providing hearing aids/glasses. Pharmacological management (e.g., low-dose haloperidol or quetiapine) is strictly reserved for severe agitation threatening immediate safety. Avoid benzodiazepines unless delirium is caused by alcohol/sedative withdrawal.
Dementia Subtypes and Pharmacotherapy
Dementia (Major Neurocognitive Disorder) involves significant decline in cognitive domains interfering with independent daily functioning.
1. Alzheimer's Disease (AD)
Accounting for 60% to 80% of cases, AD pathologically features extracellular beta-amyloid plaques and intracellular hyperphosphorylated tau tangles. Presentation includes insidious short-term memory loss, followed by executive dysfunction, aphasia, apraxia, and agnosia.
- Cholinesterase Inhibitors (AChEIs): First-line for mild-to-moderate AD. Donepezil (5–10 mg daily), Rivastigmine (oral or patch), and Galantamine. They increase synaptic acetylcholine. Adverse effects include GI distress, vagotonic bradycardia, and syncope. Transdermal rivastigmine reduces GI side effects.
- NMDA Receptor Antagonist: Memantine (5–10 mg BID or 28 mg ER daily) is indicated for moderate-to-severe AD. It blocks pathological N-methyl-D-aspartate receptor stimulation by excess glutamate. Memantine can be used alone or combined with an AChEI.
2. Vascular Dementia (VaD)
Caused by cerebrovascular disease (ischemic strokes or microvascular small-vessel disease). Classically presents with a stepwise decline in cognitive function, early executive dysfunction, apathy, and focal motor signs. Management relies on cardiovascular risk factor modification (blood pressure < 130/80 mmHg, statins, antiplatelet therapy).
3. Lewy Body Dementia (LBD)
Caused by alpha-synuclein protein deposition (Lewy bodies). Diagnostic triad:
- Fluctuating cognition with variations in attention.
- Recurrent detailed visual hallucinations.
- Spontaneous parkinsonism (bradykinesia, rigidity, resting tremor).
Patients exhibit REM Sleep Behavior Disorder and autonomic dysfunction. Severe Neuroleptic Sensitivity Warning: Typical antipsychotics (e.g., haloperidol) can precipitate severe extrapyramidal toxicity, neuroleptic malignant syndrome, or death. Low-dose quetiapine or pimavanserin are preferred if antipsychotics are required.
4. Frontotemporal Dementia (FTD)
Includes behavioral variant FTD (early disinhibition, hyperorality, apathy) and primary progressive aphasia. Onset occurs earlier (50–65 years). Memory is spared early on. AChEIs are ineffective; SSRIs or trazodone manage behavioral symptoms.
Standardized Cognitive Screening Tools
- MMSE: 30-point tool (score < 24 suggests impairment). Influenced by education; lacks sensitivity for MCI.
- MoCA: 30-point tool highly sensitive for MCI and executive deficits (cutoff < 26 points indicates impairment).
- Mini-Cog: Rapid 3-minute screen combining 3-item recall with a clock drawing test. Recalling 0 items indicates dementia; 3 items indicates normal cognition. Recalling 1–2 items uses clock drawing as tiebreaker (abnormal clock = cognitive impairment).
An 82-year-old patient is brought to the clinic by her daughter, who reports that the patient has experienced a cognitive decline over the last 3 years. The patient has a history of hypertension, hyperlipidemia, and peripheral artery disease. The daughter notes that her mother's decline occurs in sudden, discrete drops followed by periods of stability. Which of the following is the most likely diagnosis?
According to the Confusion Assessment Method (CAM), which of the following combinations of clinical features is required to confirm a diagnosis of delirium?
An 80-year-old patient with Lewy Body Dementia presents with severe agitation driven by vivid visual hallucinations of intruders in his home. Which of the following medication classes must be strictly avoided due to the risk of severe extrapyramidal toxicity and life-threatening neuroleptic sensitivity?
A 71-year-old patient presents with mild memory complaints and executive dysfunction but remains fully independent in instrumental activities of daily living. Which cognitive screening tool is most sensitive for detecting Mild Cognitive Impairment (MCI)?